{
  "id": 19535,
  "url": "https://www.federalregister.gov/documents/2026/08/17/2026-16727/hematology-and-pathology-devices-reclassification-of-in-situ-hybridization-test-systems-for-use-with",
  "title": "Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product",
  "summary": "The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary t",
  "authors": null,
  "category": "policy",
  "topics": "regulation,healthcare",
  "orgs": null,
  "regions": null,
  "published_at": "2026-08-15T05:10:17.122Z",
  "fetched_at": "2026-08-15T05:10:17.122Z",
  "source_slug": "fedreg",
  "source_name": "US Federal Register",
  "source_homepage": "https://www.federalregister.gov",
  "ethics_ai_record_url": "https://ethics.ai/record/19535",
  "original_url": "https://www.federalregister.gov/documents/2026/08/17/2026-16727/hematology-and-pathology-devices-reclassification-of-in-situ-hybridization-test-systems-for-use-with",
  "evidence_status": "source-only",
  "attribution": "via ethics.ai"
}